Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 6Phase 1/2 2Phase NA 1

Status

Withdrawn 2Recruiting 2Completed 2

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 18Other hematologic neoplasm 14CNS 8Plasma cell 6Genitourinary 4Sarcoma 3Dermatologic 2Tumor-Agnostic 1Thoracic 1Myeloid 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Multiple Myeloma 6Recurrence 1Neoplasms, Plasma Cell 1

Interventions

Dexamethasone 139Lenalidomide 75Cyclophosphamide 73Bortezomib 73Calcium Dobesilate 57fludarabine 49pomalidomide 43daratumumab 39fludarabine phosphate 34carfilzomib 33Melphalan 29dexamethasone acetate 24dexamethasone 21-phosphate 24auricularum 22Filgrastim 18Whole-Body Irradiation 15Biopsy 14ixazomib 13isatuximab 13Magnetic Resonance Spectroscopy 13Granulocyte Colony-Stimulating Factor 13Vorinostat 12Tacrolimus 12Specimen Handling 12Sirolimus 12Peripheral Blood Stem Cell Transplantation 12venetoclax 11belantamab mafodotin 11Rituximab 11Panobinostat 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × Leukapheresis × Plasma cell × Clear all
NCT03710421 2026-04-15

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

City of Hope Medical Center

Phase 1 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma

NCT07340853 2026-03-10

CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma

University of California, San Francisco

Phase 1 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma

NCT05950113 2024-05-01

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Jonsson Comprehensive Cancer Center

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma

NCT03338972 2023-09-08

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

Fred Hutchinson Cancer Center

Phase 1 Completed
28 enrolled 18 charts
Plasma cell

Multiple Myeloma

NCT03506802 2020-07-24

NYSCT MM

Jonsson Comprehensive Cancer Center

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma

NCT00089453 2012-04-19

Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant

University of Arkansas

Phase 1 Completed
10 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡